Seattle Genetics, Inc. is a biotechnology company that engages in the development and commercialization of antibody-based therapies for the treatment of cancer. It has products that include Adcetris and Padcev. It is a company that is advancing a pipeline of novel therapies for solid tumors and blood-related cancers.
As Seattle Genetics expands business globally, its name has been rebranded as Seagen. The company had obtained FDA approvals for two cancer drugs and it partnered with Merck for a Phase II antibody-drug conjugate and a marketed drug.
The company was with a single product in the market, Adcetris (brentuximab vedotin), a drug that got approval in 2011 for Hodgkin’s lymphoma and approved for anaplastic large-cell lymphoma, a type of T-cell non-Hodgkin’s lymphoma. Subsequently, it won approval for its second product, Padcev (enfortumab vedotin-ejfv), for locally advanced or metastatic urothelial cancer, and it received a nod for Tukysa (tucatinib), for HER2-positive breast cancer.